Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that Jay Markowitz, M.D., has joined the company as Senior Vice President, Portfolio Management. Dr. Markowitz has 15 years of experience as a leading institutional investor and analyst in the biopharmaceutical sector. He was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager.
“Jay is a powerful addition to our leadership team at a very important time for the company as our pipeline continues to grow and diversify,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. “Jay’s deep scientific and medical expertise, coupled with his incredible track record as a leading biopharma portfolio manager and analyst, will help Regeneron further refine our portfolio strategy in order to bring important new medicines to patients as quickly and efficiently as possible.”
Dr. Markowitz will work closely with other scientific and development leaders on portfolio evaluation and decision making as well as assessing external opportunities.
“Regeneron stands out as a company with a robust, diverse pipeline and a deep productive scientific and technological engine,” said Dr. Markowitz. “I am thrilled to join this great team that is advancing important and promising potential treatments for people with a number of serious diseases.”
Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine.
Dr. Markowitz received his undergraduate degree from Columbia University and his M.D. from Duke University. He completed a fellowship in transplant surgery at the UCLA Medical Center, a surgical residency at Massachusetts General Hospital, and a Research Fellowship in Cellular and Molecular Immunology at the Harvard School of Public Health. (Original Source)
Shares of Regeneron Pharmaceuticals are currently rising 1.28% to $384.57, or up $4.87 in pre-market trading Wednesday. REGN has a 1-year high of $524.67 and a 1-year low of $325.35. The stock’s 50-day moving average is $383.59 and its 200-day moving average is $387.77.
On the ratings front, Regeneron Pharmaceuticals has been the subject of a number of recent research reports. In a report released yesterday, RBC analyst Michael Yee reiterated a Buy rating on REGN, with a price target of $626, which represents a potential upside of 65% from where the stock is currently trading. Separately, on December 20, BMO’s Matthew Luchini initiated coverage with a Hold rating on the stock and has a price target of $419.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Michael Yee and Matthew Luchini have a yearly average loss of -4.2% and a return of 9.8% respectively. Yee has a success rate of 44% and is ranked #4072 out of 4351 analysts, while Luchini has a success rate of 55% and is ranked #1525.
Overall, 8 research analysts have assigned a Hold rating and 6 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $435.00 which is 14.6% above where the stock closed yesterday.
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma and atopic dermatitis. Its products include EYLEA (aflibercept) injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST (rilonacept), which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and PRALUENT (alirocumab) Injection for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL- C.